A Phase II Study Of BIBF 1120 as Second-line Treatment for Patients With Small Cell Lung Cancer.

Trial Profile

A Phase II Study Of BIBF 1120 as Second-line Treatment for Patients With Small Cell Lung Cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Actual initiation date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 04 Nov 2011 Planned initiation date changed from 1 Oct 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top